Search For "dcgi"
Expert panel recommends DCGI to permit Dr Reddy's Lab to conduct phase 2,3
Updated : 5 years, 4 months ago IST
New Delhi [India], October 17 (ANI): The expert committee of Drugs Controller General of India (DCGI) on Friday recommended granting permission to Dr Reddy's Laboratories for conducting phase 2 clinical trials of Russian COVID-19 vaccine candidate, Sputnik V, in India, government officials s
Read More
Dr Reddy's Lab submits revised protocol to DCGI to conduct phase 2,3 clini
Updated : 5 years, 5 months ago IST
New Delhi [India], October 13 (ANI): Indian drug maker Dr Reddy's Laboratories (DRL) has submitted a revised application to the Drugs Controller General of India (DCGI) seeking his approval to conduct phase 2 and 3 clinical trials of the Russian COVID-19 vaccine Sputnik V in India, a governm
Read More
DCGI directs Dr Reddy's lab to furnish fresh protocol to seek approval for
Updated : 5 years, 5 months ago IST
New Delhi [India], October 6 (ANI): In the latest development, the Drugs Controller General of India (DCGI) expert panel has directed the pharma giant Dr Reddy's Laboratories (DRL) to submit a revised protocol for performing phase 2,3 clinical trials of the Russian COVID-19 vaccine (Sputnik
Read More
Dr Reddy's Laboratories seeks DCGI permission to conduct Phase III trials
Updated : 5 years, 5 months ago IST
New Delhi [India], October 2 (ANI): Indian pharma giant Dr Reddy's Laboratories (DRL) has submitted an application to the Drugs Controller General of India (DCGI) for its approval to perform Phase III clinical trials of the Russian COVID-19 vaccine Sputnik V in India, a government officia
Read More
DCGI issues guidelines for pharma giants manufacturing COVID-19 vaccine
Updated : 5 years, 5 months ago IST
New Delhi [India], September 23 (ANI): The Drugs Controller General of India (DCGI) has issued a new set of guidelines, focusing on safety, immunogenicity and efficacy parameters for pharma giants who are developing COVID-19 vaccines.
Read More
First cost, time-effective CRISPER test for Covid-19 gets nod for commerc
Updated : 5 years, 5 months ago IST
New Delhi [India], September 20 (ANI): The Drugs Controller General of India (DCGI) has given approval to the Tata Group for the launch of India's first Clustered Regularly Interspaced Short Palindromic (CRISPR) Covid-19 test for commercial launch.
Read More
DCGI approves India's first CRISPR Covid-19 test developed by the Tata Gro
Updated : 5 years, 5 months ago IST
New Delhi [India], September 19 (ANI): The Drug Controller General of India (DCGI), on Saturday gave approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) test, developed by the Tata Group and CSIR-IGIB (Institute of Genomics a
Read More
DCGI gives nod to Serum Institute to restart phase 2,3 trials for COVID-19
Updated : 5 years, 5 months ago IST
New Delhi [India], September 16 (ANI): The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSM
Read More
Serum Institute to resume COVID-19 vaccine trials in India after DCGI nod
Updated : 5 years, 6 months ago IST
New Delhi [India], September 12 (ANI): Hours after clinical trials for AstraZeneca and Oxford University coronavirus vaccine resumed on Saturday in the UK, pharma major Serum Institute of India (SII) said it will resume the trials in India once Drugs Controller General of India (DCGI) gives
Read More
DCGI directs Serum Institute to suspend any new recruitment in phase 2, 3
Updated : 5 years, 6 months ago IST
New Delhi [India], September 12 (ANI): The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.
Read More
Serum Institute says will adhere to DCGI instructions after show cause ove
Updated : 5 years, 6 months ago IST
New Delhi [India], September 9 (ANI): Hours after the Drugs Controller General of India (DCGI) issued a show-cause notice Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts about
Read More
DCGI sends show cause notice to Serum Institute for not pausing trial of
Updated : 5 years, 6 months ago IST
New Delhi [India], September 9 (ANI): The Drugs Regulator General of India (DCGI) has issued a show-cause notice to pharma giant Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts
Read More